Clinical Trial Update: A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial results for Mircera (methoxy polyethylene glycol-epoetin beta) in maintenance treatment of anemia in adults on hemodialysis were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2016-05-13